FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Beyond Medical Technologies Inc. (the “Issuer” or the “Company”).

Trading Symbol: DOCT

Number of Outstanding Listed Securities: 79,139,750

Date: July 04, 2022

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Beyond Medical Technologies Inc. (the “Company”), through its wholly-owned subsidiary of Micron Technologies Inc. has been manufacturing Class 1 Medical Devices pursuant to its Medical Device Establishment License from Health Canada and medical device registration with U.S. Food and Drug Administration.

The Company continues to manufacture 3-ply surgical face masks (Model F2100), face mask filters (Model F98) and N95 (Model 8800) respirators. The company’s 3-ply face masks have been or are highly ranked seller in their respective categories.

As the demand for the face masks rapidly declined over the previous months and the lifting of mask mandate by provincial authorities at public locations. The company is reviewing its face mask manufacturing business to operate at a reduced capacity or potentially terminate its mask manufacturing business. Also the company is interested in investigating business opportunities in sectors which can offer attractive shareholder return and offer growth opportunities with the infusion of capital.

1. Provide a general overview and discussion of the activities of management.

**The Company has been manufacturing personal protective equipment (PPE) and has an investment in digital telehealth platform in Kayan Health.
Kayan Health is an artificial-intelligence powered health communications platform that allows doctors to communicate with their patients and monitor them remotely.**

**During the year ended December 31, 2021, management determined the investment was not recoverable and recognized as a fair value loss in the statement of loss.**

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or strategic plan oil and gas or other reports required under Ontario securities law.

None.

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the dispositions was to a Related Person of the Issuer and provide details of the relationship.

None.

1. Describe the acquisition of new customers or loss of customers.

None.

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

1. Report on any employee hiring’s, terminations or lay-offs with details of anticipated length of lay-offs.

None.

1. Report on any labour disputes and resolutions of those disputes if applicable.

None.

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None.**

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

1. Provide details of any securities issued and options or warrants granted.

**None**

1. Provide details of any loans to or by Related Persons.

None.

1. Provide details of any changes in directors, officers or committee members.

None.

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

The Issuer’s business involves certain risks and uncertainties that are inherent to the Issuer’s industry. Please refer to the “Risks Related to The Business” section of the Issuer’s management discussion and analysis for the year ended December 31, 2021, which is available on SEDAR at [www.sedar.com](http://www.sedar.com).

As the demand for the face masks rapidly declined over the previous months and the lifting of mask mandate by provincial authorities at public locations. The company is reviewing its face mask manufacturing business to operate at a reduced capacity or potentially terminate its mask manufacturing business. Also the company is interested in investigating business opportunities in sectors which can offer attractive shareholder return and offer growth opportunities with the infusion of capital.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: July 04, 2022

 Kal Malhi
Name of Director or Senior Officer

 “Kal Malhi”

 Signature

Interim President and CEO
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Official Capacity

|  |  |  |
| --- | --- | --- |
| *Issuer Details*Name of IssuerBeyond Medical Technologies Inc. | For Month EndJune 30, 2022 | Date of ReportYY/MM/D2022/07/04 |
| Issuer AddressSuite 725-6388, No.3 Road |
| City/Province/Postal CodeRichmond, BC – V6Y 0L4 | Issuer Fax No.N/A | Issuer Telephone No.(604) 805-4602 |
| Contact NameKal Malhi | Contact PositionInterim President and CEO | Contact Telephone No.(604) 805-4602 |
| Contact Email Addresskal@bullruncapital.ca | Web Site Addresswww.beyondmd.ca |